About this trial
This study is to assess the addition of 3D ultrasound guidance during standard care ablation or biopsies of liver or kidney tumours. 3D ultrasound only differs from conventional 2D ultrasound in that the ultrasound transducer is mounted on a special assembly that moves the transducer in precise, stepped movements while a succession of 2D images are collected by the computer. Special software written specifically for 3D ultrasound precisely aligns these 2D images into a 3-demensional volume , allowing area in question to be viewed in many different planes. 3D ultrasound is a safe, fast, non-invasive imaging procedure. Ultrasound images will be checked against the pre- and post- procedure CT images to make sure the tumours were completely removed or properly targeted during biopsy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
• Patients who are scheduled for standard care liver or kidney ablation or biopsy
Disqualifiers
None
Trial population
Patients who meet the inclusion / exclusion criteria, who are already scheduled for a liver or kidney tumour ablation or biopsy will be selected for the study.
Trial design
Cohort
Prospective
Treatments tested in this trial
Ablation
DeviceThe medical device will passively record image data during the standard care ablation
Biopsy
DeviceThe medical device will passively record image data during the standard care biopsy
Treatment groups
Trial outcomes
Primary outcomes
Needle Guidance Intervention
The objective of this study is to use 3D ultrasound in addition to standard care ultrasound to guide the ablation needles in destroying focal tumours within the diseased organ
Sponsors and contacts
Click on the lead sponsor to view all of their trials.